Studies showed that miRNA-21, miRNA-106a, and miRNA-182 target PDCD4, increasing drug resistance of pancreas cancer, CML, NSCLC, and ovarian cancer to GEM [172] and CDDP [60, 90], respectively. The gene discussed is PDCD4; the disease is non-small cell lung carcinoma.